SCHEMBL1407585

SCHEMBL1407585

O=C(c1cccc(COc2cccc(-c3c4cccc(C(F)(F)F)c4nn3Cc3ccc(Cl)cc3F)c2)c1)N1CCOCC1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 15/20 0.54
NR1H3 Q13133 15/20 0.54
NPC1 O15118 1/20 0.46
TP53 P04637 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALDH1A1 P00352 1/20 0.46
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
NR1I2 O75469 2/20 0.42
NR3C1 P04150 2/20 0.42
AR P10275 1/20 0.42
RXRA P19793 1/20 0.42
MRGPRX4 Q96LA9 1/20 0.42
MGLL Q99685 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1408079 0.90 NR1H2 (0.58) NR1H2NR1H3NPC1RAB9ANR1I2
SCHEMBL1407911 0.87 NR1H2 (0.59) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1408169 0.86 NR1H2 (0.61) NR1H2NR1H3RAB9ANR1I2NR3C1
SCHEMBL1407460 0.85 NR1H2 (0.57) NR1H2NR1H3NPC1RAB9ASMN1; SMN2
SCHEMBL1408034 0.85 NR1H2 (0.55) NR1H2NR1H3NPC1RAB9ASMN1; SMN2
SCHEMBL1407568 0.84 NR1H2 (0.56) NR1H2NR1H3NPC1TP53RAB9A
SCHEMBL1408178 0.84 NR1H2 (0.61) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1408139 0.84 NR1H2 (0.55) NR1H2NR1H3NPC1RAB9ASMN1; SMN2
SCHEMBL1407920 0.83 NR1H2 (0.69) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1408476 0.83 NR1H2 (0.60) NR1H2NR1H3NR1I2NR3C1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US claimed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US claimed
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 NR1H2 1/4885NR1H3 2/4885NPC1 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.